Viral Vectors & Plasmid DNA Manufacturing Market Poised for Strong Growth Driven by Rising Gene Therapy Adoption

According to Precedence Research, the global viral vectors & plasmid DNA manufacturing market size was calculated at USD 6.26 billion in 2024 and is projected to grow to around USD 26.66 billion by 2034, growing at a CAGR of 15.59% from 2025 to 2034. The viral vectors & plasmid DNA manufacturing market is driven by the increasing adoption of gene therapies for rare and genetic diseases

Global Outlook

The viral vectors & plasmid DNA manufacturing market has experienced growth in recent years, owing to the treatment, like DNA-based vaccines and gene therapy are moving from research to real treatments in recent years. Also, by combining molecular biology, biotechnology, and clean manufacturing, the industry is likely to gain global attention in the upcoming years.

Market Opportunities

• The automated and modular biomanufacturing systems are likely to create lucrative opportunities for the market during the projected period.
• The advancement of global healthcare infrastructure is likely to provide greater advantage to the industry players in the coming years.

Key Growth Factors

• The usage of artificial intelligence and data analytics has been driving the industry's potential in recent years.
• The shift towards cell-free DNA synthesis has contributed to the industry’s growth in the past few years.

Market Restraint

• The higher production cost and complex regulatory process are expected to hinder industry growth in the coming years.

Segmental Outlook

By Vector Type

What made the AAV Segment Dominant in the Viral Vectors & Plasmid DNA Manufacturing Market in 2024?

The AAV segment generated the greatest revenue share in 2024, owing to its being considered the most stable, safe, and effective for gene therapy. Moreover, by having the ability to deliver genetic material into human cells without causing any diseases, the AAV has gained major industry attention in recent years.

By Workflow Type

What made the Downstream Processing Segment Dominant in the Viral Vectors & Plasmid DNA Manufacturing Market in 2024?

The downstream processing segment generated the greatest revenue share in 2024 because of its greater focus on purifying and refining viral vectors and plasmid DNA. Furthermore, by improving efficiency and yield, the advanced filtration, polishing systems, and chromatography have created a sophisticated consumer base in recent years.

By Application Type

The vaccinology segment generated the greatest revenue share in 2024 because viral vectors and plasmid DNA are now key tools for next-generation vaccines. COVID-19 vaccines proved how fast and effective DNA and viral-vector platforms can be. These technologies allow quick design changes when new viruses appear

By Disease

The cancer segment generated the greatest revenue share in 2024 because gene and cell therapies are being used to attack tumors in smarter ways. Viral vectors deliver modified genes that help the body's immune system recognize and destroy cancer cells.

By End Use

The research institutes segment generated the greatest revenue share in 2024, because they are the backbone of discovery and early testing in viral vector and plasmid DNA development. Universities and national labs perform basic research that later turns into commercial therapies.

Geographical Outlook

North America

North America dominated the viral vectors & plasmid DNA manufacturing market due to the presence of the most advanced regulatory clarity and biotech ecosystem in the current period. Moreover, the major biotech companies and pharmaceutical giants have headquarters in this region, which is boosting industry potential.

Asia Pacific 

Asia Pacific is expected to emerge at the fastest CAGR during the forecast period of 2025 to 2034, due to the regional countries shift towards heavy advancements in the gene therapy infrastructure and biomanufacturing in recent years, with huge investments. Moreover, the governments push towards local production by releasing funds for the advanced research centers is likely to create greater opportunities in the industry.

Strategic Moves by Key Players

• In August 2025, Probio opened its flagship U.S. plasmid DNA and viral vector GMP manufacturing facility. At 96,000 square feet, the site was designed to help gene and cell therapy developers with complete end-to-end services. This facility strengthened Probio's global presence as a CDMO and provided enhanced scalability and speed of production. 
  (Source: https://www.prnewswire.com)

Viral Vectors & Plasmid DNA Manufacturing Market Companies

• Novasep
• Aldevron
• MerckWaismanBiomanufacturing
• Creative Biogene
• The Cell and Gene Therapy Catapult
• Cobra Biologics
• uniQure N.V.
• Addgene
• FUJIFILM Holdings Corporation
• Oxford Biomedicaplc
• Takara Bio Inc.

Segments Covered in the Report

By Vector Type

• Adenovirus
• Plasmid DNA
• Lentivirus
• Retrovirus
• AAV
• Others

By Application

• Gene Therapy
• Antisense &RNAi
• Cell Therapy
• Vaccinology

By Workflow

• Upstream Processing
  • Vector Recovery/Harvesting
  • Vector Amplification & Expansion
• Downstream Processing
  • Fill-finish
  • Purification

By End-User

• Biopharmaceutical and Pharmaceutical Companies
• Research Institutes

By Disease

• Genetic Disorders
• Cancer
• Infectious Diseases
• Others

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• Rest of the World

Source:  https://www.precedenceresearch.com/viral-vectors-and-plasmid-dna-manufacturing-market